Modified tuberculosis vaccine as therapy against bladder cancer

March 5, 2020

The Max Planck Insitute for Infection Biology is sharing news of interest to the Immunology Community.

Therapy with VPM1002 is effective in bladder cancer patients

The human immune system can recognize and eliminate not only germs but also cancer cells. This is why treatments with weakened germs can help the immune system it ist fight against cancer.

The Max Planck Insitute for Infection Biology has developed a vaccine against TB which is currently in phase III trial. Less known is that this vaccine is also tested for treatment of bladder cancer and it has now shown a remarkable outcome in a clinical trial in preventing cancer recurrence.

clinical trial no.: NCT02371447 (https://clinicaltrials.gov/ct2/show/NCT02371447)

More News

Deadline Extension – Nominations for IUIS Elections 2022

June 30, 2022

SCGES Webinars in June – on Gender Equality

June 2, 2022Gender Equality Committee (GEC)

Menarini Prize for Outstanding Woman Immunologist

May 31, 2022Gender Equality Committee (GEC)

Funding Opportunity from ICLAS

May 23, 2022

2022 Edition: Day of Immunology

May 19, 2022

2022 World Laureates Association Prize (WLA Prize)

May 4, 2022

2022 International Day of Immunology

April 29, 2022

#ThankYouImmunology video campaign for the 2022 Day of Immunology

April 27, 2022

Michelson Prizes

April 25, 2022